GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (XSWX:SDZ) » Definitions » Change In Payables And Accrued Expense

Sandoz Group AG (XSWX:SDZ) Change In Payables And Accrued Expense : CHF0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Change In Payables And Accrued Expense?

Sandoz Group AG's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was CHF0 Mil. It means Sandoz Group AG's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Sandoz Group AG's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was CHF0 Mil. It means Sandoz Group AG's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .


Sandoz Group AG Change In Payables And Accrued Expense Historical Data

The historical data trend for Sandoz Group AG's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Change In Payables And Accrued Expense Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Change In Payables And Accrued Expense
- -

Sandoz Group AG Semi-Annual Data
Dec22 Dec23
Change In Payables And Accrued Expense - -

Sandoz Group AG Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sandoz Group AG Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG (XSWX:SDZ) Business Description

Industry
Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (XSWX:SDZ) Headlines

No Headlines